Efficacy and safety of molsidomine once-a-day in patients with stable angina pectoris

International Journal of Cardiology

Volumn 98, Issue 1, 2005, Pages 79-89

  Messin, Roger ^a   Opolski, Grzegorz ^b   Fenyvesi, Tamas ^c   Carreer Bruhwyler, Fabienne ^d   Dubois, Claude ^a   Famaey, Jean Pierre ^a   Géczy, Joseph ^a  

^a Therabel Pharma Belgium   (Belgium)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^d Ind Stat Ctr SquarePoint P   (Belgium)

Author keywords

Exercise testing; Molsidomine; Once a day; Placebo controlled study; Stable angina

Indexed keywords

CORUNO; CORVATARD; ISOSORBIDE DINITRATE; MOLGEOM UNO; MOLSIDOMINE; PLACEBO;

ADULT; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BICYCLE ERGOMETRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATINE KINASE BLOOD LEVEL; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGUS CARCINOMA; EXERCISE TOLERANCE; FEMALE; HEADACHE; HEART INFARCTION; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERKALEMIA; HYPOTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STABLE ANGINA PECTORIS; STATISTICAL SIGNIFICANCE; UNSTABLE ANGINA PECTORIS;

ADULT; AGED; ANGINA PECTORIS; BLOOD PRESSURE; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; MOLSIDOMINE; NITRIC OXIDE DONORS; PATIENT COMPLIANCE; QUALITY OF LIFE; TIME FACTORS; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 12844273903     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2004.01.007     Document Type: Article

References (21)

1. Rosenkranz B., Winkelmann B.R., Parnham M.J. Clinical pharmacokinetics of molsidomine. Clin. Pharmacokinet. 30:1996;372-384
2. Hug J., Hasenfuss G., Wollschläger H., et al. Koronardilatation nach intrakoronar verabreichtem SIN-1 bzw. intravenöser Molsidomin-Gabe. Coronary dilation after intracoronary administration of SIN-1 and intravenous molsidomine administration Med. Klin. 89(Suppl. 2):1994;34-37
3. Münzel T., Kurz S., Heitzer T., et al. Auswirkungen einer intravenösen Gabe von Nitroglycerin bzw. SIN-1 oder Molsidomin auf den Epikardarterienduchmesser bei Patienten mit stabiler koronarer Herzkrankheit. Effects of intravenous administration of nitroglycerin and SIN-1 or molsidomine on epicardial arterial diameter in patients with stable coronary heart disease Med. Klin. 89(Suppl. 2):1994;38-41
4. 2+ handling in patients with suspected coronary artery disease: ex vivo and in vitro studies. Thromb. Haemost. 83:2000;752-758
5. Ignarro L.J., Buga G.M., Wood K.S., et al. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc. Natl. Acad. Sci. U.S.A. 84:1987;9265-9269
6. Kirsten R., Nelson K., Kirsten D., et al. Clinical pharmacokinetics of vasodilators. Part II. Clin. Pharmacokinet. 35:1998;9-36
7. Fach W.A., Becker H.J. Wirkdauer und Dosis-Wirkungs-Beziehung von Molsidomin bei Patienten mit Koronarer Herzkrankheit. (effect duration and dose-response relation of molsidomine in patients with coronary artery disease) Z. Kardiol. 73:1984;613-622
8. Redwood D.R., Rosing D.R., Goldstein R.E., et al. Importance of the design of an exercise protocol in the evaluation of patients with angina pectoris. Circulation. 43:1971;618-628
9. Jones B., Jarvis P., Lewis J.A., et al. Trials to assess equivalence: the importance of rigorous methods. Br. Heart J. 313:1996;36-39
10. Messin R., Boxho G., De Smedt J., et al. Acute and chronic effect of molsidomine extended release on exercise capacity in patients with stable angina pectoris, a double-blind cross-over clinical trial versus placebo. J. Cardiovasc. Pharmacol. 25:1995;558-563
11. Tofler G., Brezinski D., Schafer A.I., et al. Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. N. Engl. J. Med. 316:1987;1514-1518
12. Rosing D.R., Brakman P., Redwood D.R., et al. Blood fibrinolytic activity in man: diurnal variation and the response to varying intensities of exercise. Circ. Res. 27:1970;171-184
13. Yasue H., Omote S., Takizawa A., et al. Circadian variation of exercise capacity in patients with Prinzmetal's variant angina: role of exercise-induced coronary arterial spasm. Circulation. 59:1979;938-948
14. 1- sympathetic activity for diurnal change in ischemic threshold in patients with stable angina. Clin. Cardiol. 21:1998;357-361
15. Joy M., Pollard C.M., Nunan T.O. Diurnal variation in exercise responses in angina pectoris. Br. Heart J. 48:1982;156-160
16. Bloom B.S. Daily regimen and compliance with treatment. BMJ. 323:2001;647
17. Spertus J.A., Dewhurst T., Dougherty C.M., et al. Testing the effectiveness of converting patients to long-acting antianginal medications: The quality of life in angina research trial (QUART). Am. Heart J. 141:2001;550-558
18. Jansen R., Niemeyer M.G., Cleophas T.J., et al. Factors influencing efficacy of nitrate therapy for stable angina pectoris: a multiple linear regression analysis. Angiology. 51:2000;1007-1012
19. van Kesteren H.A., Withagen A.J. A comparative study of once-daily amlodipine versus twice-daily diltiazem controlled release (CR) in the treatment of stable angina pectoris. Amlodipine Study Group. Cardiovasc. Drugs Ther. 12(Suppl. 3):1998;233-237
20. Chugh S.K., Digpal K., Hutchinson T., et al. A randomized, double-blind comparison of the efficacy and tolerability of once-daily modified-release diltiazem capsules with once-daily amlodipine tablets in patients with stable angina. J. Cardiovasc. Pharmacol. 38:2001;356-364
21. Schug B.S., Brendel E., Wonnemann M., et al. Dosage form-related food interaction observed in a marketed once-daily nifedipine formulation after a high-fat American breakfast. Eur. J. Clin. Pharmacol. 58:2002;119-125